Level A in vitro-in vivo correlation (IVIVC) model with Bayesian approach to formulation series

Journal of Pharmaceutical Sciences

Volumn 95, Issue 7, 2006, Pages 1595-1605

  Kortejarvi H ^a   Malkki, J ^a   Marvola, M ^b   Urtti, A ^b,c   Yliperttula, M ^a   Pajunen, P ^d  

^a ORION CORPORATION   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d AALTO UNIVERSITY   (Finland)

Author keywords

Bayesian; Bioequivalency; Biowaiver; in vitro in vivo correlations (IVIVC); Internal and external predictability; Levosimendan; Mathematical model

Indexed keywords

LEVOSIMENDAN;

AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; COMPARTMENT MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SOLUBILITY; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; NORMAL HUMAN; PREDICTION; PROBABILITY;

EID: 33745902525     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20592     Document Type: Article

References (41)

1. Guidance for Industry, Extended Release Oral Dosage Forms. 1997. Development, evaluation, and application of in vitro/in vivo correlations. Ed. Rockville, MD: Food and Drug Administration.
2. Note for Guidance on Quality of Modified-release Products. 1999. A: oral dosage forms, B: transdermal dosage forms section I Quality. Ed. London, UK: Committee for Proprietary Medicinal Products.
3. Guidance for Industry, SUPAC-MR. 1997. Modified-release solid oral dosage forms. Rockville, MD: Food and Drug Administration.
4. Eddington ND, Marroum P, Uppoor R, Hussain A, Augsburger L. 1998. Development and internal validation of an in vitro-in vivo correlation for a hydrophilic metoprolol tartrate extended release tablet formulation. Pharm Res 15:466-473.
5. Mahayni H, Rekhi GS, Uppoor RS, Marroum P, Hussain A, Augsburger LL, Eddington ND. 2000. Evaluation of external predictability of an in vitro-in vivo correlation for an extended-release formulation containing metoprolol tartrate. J Pharm Sci 89:1354-1361.
6. Modi N, Lam A, Lindemulder E, Wang B, Gupta SK. 2000. Application of in vitro-in vivo correlations (IVIVC) in setting formulation release specifications. Biopharm Drug Dispos 21:321-326.
7. Sirisuth N, Eddington ND. 2000. Influence of stereoselective pharmacokinetics in the development and predictability of an IVIVC for the enantiomers of metoprolol tartrate. Pharm Res 17:1019-1025.
8. Balan G, Timmins P, Greene DS, Marathe PH. 2001. In vitro-in vivo correlation (IVIVC) models for metformin after administration of modified-release (MR) oral dosage forms to healthy volunteers. J Pharm Sci 9:1176-1185.
9. Dalton JT, Straughn AB, Dickason DA, Grandolfi GP. 2001. Predictive ability of level A in vitro-in vivo correlation for RingCap controlled-release acetaminophen tablets. Pharm Res 18:1729-1734.
10. Sirisuth N, Augsburger LL, Eddington ND. 2002. Development and validation of a non-linear IVIVC model for diltiazem extended release formulation. Biopharm Drug Dispos 23:1-8.
11. Sirisuth N, Eddington ND. 2002. The influence of first pass metabolism on the development and validation of an IVIVC for metoprolol extended release tablets. Eur J Pharm Biopharm 53:301-309.
12. Mauger DT, Chinchilli VM. 1997. In vitro-in vivo relationship for oral extended-release drug products. J Biopharm Stat 7:565-578.
13. Bigora S, Piscitelli D, Dowell J, Butler J, Farrell C, Devane J, Young D. 1997. Use of nonlinear mixed effects modelling in the development of in vitro-in vivo correlations. In: Young D, Devane J, Butler J, editors. Advances in experimental medicine and biology, vol. 423, In vitro-In vivo correlations. New York: Plenum Press, pp 207-215.
14. Verotta D. 1997. A general framework for non-parametric subject-specific and population deconvolution methods for in vivo-in vitro correlation. In: Young D, Devane J, Butler J, editors. Advances in experimental medicine and biology, vol. 423, In vitro-In vivo correlations. New York: Plenum Press, pp 43-52.
15. Dunne A, O'Hara T, Devane J. 1999. A new approach to modelling the relationship between in vitro and in vivo drug dissolution/absorption. Stat Med 18:1865-1876.
16. O'Hara T, Hayes S, Davis J, Devane J, Smart T, Dunne A. 2001. In vitro-in vivo correlation (IVIVC) modeling incorporating a convolution step. J Pharmacokin and Pharmacodyn 28:277-297.
17. Pitsiu M, Sathyan G, Gupta S, Verotta D. 2001. A semiparametric deconvolution model to establish in vitro-in vivo correlation applied to OROS oxybutynin. J Pharm Sci 90:702-712.
18. Qiu Y, Garren J, Samara E, Cao G, Abraham C, Cheskin HS, Engh KR. 2003. Once-a-day controlled-release dosage form of divalproex sodium II: development of a predictive in vitro drug release method. J Pharm Sci 92:2317-2325.
19. Gelman A, Bois F, Jiang J. 1996. Physiological pharmacokinetic analysis using population modeling and informative prior distributions. J Am Stat Assoc 91:1400-1412.
20. Sheiner LB, Beal S, Rosenberg B, Marathe VV. 1979. Forecasting individual pharmacokinetics. Clin Pharmacol Ther 26:294-305.
21. Thomson AH, Whiting B. 1992. Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet 22:447-467.
22. del Mar Fernández de Gatta M, Garciá MJ, Lanao JM, Domínguez-Gil A. 1996. Bayesian forecasting in paediatric populations. Clin Pharmacokinet 31:325-330.
23. max: a computer simulation analysis. Int J Clin Pharmacol Ther 37:439-445.
24. Leger F, Debord J, Le Meur Y, Rousseau A, Büchler M, Lachâtre G, Paintaud G, Marquet P. 2002. Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants. Clin Pharmacokinet 41:71-80.
25. Rousseau A, Sabot C, Delepine N, Delepine G, Debord J, Lachâtre G, Marquet P. 2002. Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma. Clin Pharmacokinet 41:1095-1104.
26. Bois FY, Smith TJ, Gelman A, Chang H-Y, Smith AE. 1999. Optimal design for a study of butadiene toxicokinetics in humans. Toxicol Sci 49:213-224.
27. Bois FY. 2000. Statistical analysis of Clewell et al. PBPK model of trichloroethylene kinetics. Environ Health Perspect 8:307-317.
28. Jonsson F, Johanson G. 2002. Physiologically based modeling of the inhalation kinetics of styrene in humans using Bayesian population approach. Toxicol Appl Pharmacol 179:35-49.
29. Huitema ADR, Mathôt RAA, Tibben MM, Schellens JHM, Rodenhuis S, Beijnen JH. 2000. Validation techniques for prediction of carboplatin exposure: application of Bayesian methods. Clin Pharmacol Ther 67:621-630.
30. Lilleberg J, Sunberg S, Nieminen MS. 1995. Dose-range study of a new calcium sensitizer, levosimendan, in patients with left venticular dysfunction. J Cardiovasc Pharmacol 26:63-69.
31. Kortejärvi H, Mikkola J, Bäckman M, Antila S, Marvola M. 2002. Development of level A, B and C in vitro-in vivo correlations for modified-release levosimendan capsules. Int J Pharm 241:87-95.
32. Jonsson EN, Antila S, Mc Fadyen L, Lehtonen L, Karlsson O. 2003. Population pharmacokinetics of levosimendan in patients with congestive heart failure. Br J Clin Pharmacol 55:544-551.
33. Karlsson M, Korkolainen T, Wikberg T. 1997. Automated analysis of levosimendan in human plasma by on-line dialysis and liquid chromatography. Biomed Chromatogr 11:54-58.
34. Wagner JG, Nelson E. 1964. Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug. J Pharm Sci 53:1392-1403.
35. Brockmeier D, Voegele D, von Hattingberg HM. 1983. In vitro-in vivo correlation, a time scaling problem? Arzneim Forsch/Drug Res 33:598-601.
36. Veng-Pedersen P, Gobburu JVS, Meyer MC, Straughn AB. 2000. Carbamazepine level A in vivo-in vitro correlation (IVIVC): a scaled convolution based predictive approach. Biopharm Drug Dispos 21:1-6.
37. Buchwald P. 2003. Direct, differential-equation based in vitro-in vivo correlation (IVIVC) method. J Pharm and Pharmacol 55:495-504.
38. Gelman A, Carlin JB, Stern HS, Rubin DB. 1995. Bayesian data analysis, 1st edn. London, New York, Washington DC: Chapman & Hall/CRC.
39. Box GEP, Tiao GC. 1973. Bayesian inference in statistical analysis. New York: Wiley.
40. Metropolis N, Ulam S. 1949. The Monte Carlo method. J Am Stat Assoc 44:335-341.
41. Sandell EP, Häyhä M, Antila S, Heikkinen P, Ottoila P, Lehtonen LA, Pentikäinen PJ. 1995. Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure. J Cardiovas Pharmacol 26:57-62.